SCHEMBL3303729

SCHEMBL3303729

Cc1nnc(C#N)c(-c2c(F)cc(F)cc2F)c1-c1ccc(Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.36
ERBB2 P04626 1/20 0.35
KDM4E B2RXH2 7/20 0.35
ALDH1A1 P00352 6/20 0.35
HPGD P15428 6/20 0.35
KMT2A Q03164 6/20 0.35
NPSR1 Q6W5P4 2/20 0.35
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX15 P16050 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
GAA P10253 2/20 0.34
PPARG P37231 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3311645 0.89 ERBB2 (0.37) ARERBB2KDM4EALDH1A1HPGD
SCHEMBL10015880 0.86 CHEK1 (0.39) KDM4EALDH1A1HPGDKMT2ANPSR1
SCHEMBL3971627 0.86 RAB9A (0.39) ALDH1A1KMT2ARAB9ANPC1HSD17B10
SCHEMBL3313721 0.83 RAB9A (0.37) ALDH1A1KMT2ARAB9ANPC1HSD17B10
SCHEMBL3309386 0.82 GAA (0.38) ERBB2KDM4EALDH1A1HPGDKMT2A
SCHEMBL1869939 0.82 RAB9A (0.36) ALDH1A1KMT2ARAB9ANPC1HSD17B10
SCHEMBL2355414 0.80 MEN1 (0.47) KDM4EKMT2ANPSR1RAB9ANPC1
SCHEMBL14010474 0.79 RAB9A (0.36) ALDH1A1KMT2ARAB9ANPC1HSD17B10
SCHEMBL12457752 0.76 MEN1 (0.37) KMT2ARAB9ANPC1HSD17B10TP53
SCHEMBL2356139 0.76 MEN1 (0.36) ALDH1A1KMT2ARAB9ANPC1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113457-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US claimed
US-20100113457-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA CROP PROTECTION, INC. (US) 2010-05-06 US disclosed
EP-2121629-A1 NOVEL PYRIDAZINE DERIVATIVES Syngeta Participations AG (CH) 2009-11-25 EP disclosed
WO-2008049584-A1 NOVEL PYRIDAZINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113457-A1 NOVEL PYRIDAZINE DERIVATIVES C3AR1, C5, C1S AR 4753/4885ERBB2 3678/4885KDM4E 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.